Inhibition of Cellular MEK/ERK Signaling Suppresses Murine Papillomavirus Type 1 1 Replicative Activities and Promotes Tumor Regression 2

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cobimetinib Sensitizes Cervical Cancer to Paclitaxel via Suppressing Paclitaxel-Induced ERK Activation

  2022cited by this paper
• A novel lineage-tracing mouse model for studying early MmuPV1 infections

  2022cited by this paper
• MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors.

  2021cited by this paper
• HPV and Recurrent Respiratory Papillomatosis: A Brief Review

  2021cited by this paper
• Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection In Vitro and In Vivo

  2021cited by this paper
• Human papillomaviruses: diversity, infection and host interactions

  2021cited by this paper
• Dynamics of papillomavirus in vivo disease formation & susceptibility to high-level disinfection-Implications for transmission in clinical settings.

  2021cited by this paper
• Mus musculus Papillomavirus 1: a New Frontier in Animal Models of Papillomavirus Pathogenesis

  2020cited by this paper
• MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects

  2020cited by this paper
• MEK2 is a critical modulating mechanism to down‐regulate GCIP stability and function in cancer cells

  2019cited by this paper
• Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

  2019cited by this paper
• Keratins in Skin Epidermal Development and Diseases

  2018cited by this paper
• Worldwide burden of cancer attributable to HPV by site, country and HPV type

  2017cited by this paper
• Host control of human papillomavirus infection and disease.

  2017cited by this paper
• Clinical implications of the interaction between HPV and HIV infections.

  2017cited by this paper
• Recent advances in preclinical model systems for papillomaviruses.

  2017cited by this paper
• Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer

  2017cited by this paper
• The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets.

  2017cited by this paper
• Current Development Status of MEK Inhibitors

  2017cited by this paper
• Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

  2016cited by this paper
• Regulation of ERK-MAPK signaling in human epidermis

  2015cited by this paper
• Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors

  2015cited by this paper
• Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia

  2015cited by this paper
• Immune Status, Strain Background, and Anatomic Site of Inoculation Affect Mouse Papillomavirus (MmuPV1) Induction of Exophytic Papillomas or Endophytic Trichoblastomas

  2014cited by this paper
• Targeting RAS–ERK signalling in cancer: promises and challenges

  2014cited by this paper
• Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease

  2014cited by this paper
• Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer

  2014cited by this paper
• Regulatory elements in the viral genome.

  2013cited by this paper
• Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.

  2013cited by this paper
• Immunosuppression Facilitates the Reactivation of Latent Papillomavirus Infections

  2013cited by this paper
• Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

  2012cited by this paper
• Therapy of human papillomavirus-related disease.

  2012cited by this paper
• The biology and life-cycle of human papillomaviruses.

  2012cited by this paper
• Contact inhibition (of proliferation) redux.

  2012cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011cited by this paper
• Binding Site Specificity and Factor Redundancy in Activator Protein-1-driven Human Papillomavirus Chromatin-dependent Transcription*

  2011cited by this paper
• Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells

  2011cited by this paper
• The TCR-mediated signaling pathways that control the direction of helper T cell differentiation.

  2010cited by this paper
• A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal

  2009cited by this paper
• E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.

  2009cited by this paper
• Characterising the local immune responses in cervical intraepithelial neoplasia: a cross‐sectional and longitudinal analysis

  2008cited by this paper
• The MEK/ERK cascade: from signaling specificity to diverse functions.

  2007cited by this paper
• Contact-dependent inhibition of EGFR signaling by Nf2/Merlin

  2007cited by this paper
• Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.

  2007cited by this paper
• Ras/Erk MAPK Signaling in Epidermal Homeostasis and Neoplasia

  2007cited by this paper
• IQGAP1 Is a Scaffold for Mitogen-Activated Protein Kinase Signaling

  2005cited by this paper
• Coordinating ERK/MAPK signalling through scaffolds and inhibitors

  2005cited by this paper
• The papillomavirus life cycle.

  2005cited by this paper
• GIT1 Functions as a Scaffold for MEK1-Extracellular Signal-Regulated Kinase 1 and 2 Activation by Angiotensin II and Epidermal Growth Factor

  2004cited by this paper
• Induction of senescence-like state and suppression of telomerase activity through inhibition of HPV E6/E7 gene expression in cells immortalized by HPV16 DNA.

  2002cited by this paper
• Ki-67, Cyclin E, and p16 INK4 Are Complimentary Surrogate Biomarkers for Human Papilloma Virus-Related Cervical Neoplasia

  2001cited by this paper
• Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.

  2000cited by this paper
• The N-terminal ERK-binding Site of MEK1 Is Required for Efficient Feedback Phosphorylation by ERK2 in Vitro and ERK Activation in Vivo *

  1999cited by this paper
• Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta.

  1999cited by this paper
• MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade.

  1998cited by this paper
• Management of cervical neoplasia in human immunodeficiency virus-infected women.

  1998cited by this paper
• Growth factor‐stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1)

  1994cited by this paper
• Signal transduction by lymphocyte antigen receptors.

  1994cited by this paper
• Immunological events in regressing genital warts.

  1994cited by this paper
• Genital warts and cervical cancer III. Subclinical papillomaviral infection and cervical neoplasia are linked by a spectrum of continuous morphologic and biologic change

  1984cited by this paper

• No citing papers are available for this paper.